SCHEDULE 13G/A: Dellora Investments Discloses Significant Stake in Tenax Therapeutics, Exceeding 10% Ownership
Beneficial Ownership Report
Dellora Investments LP and its affiliates have disclosed a significant passive ownership stake in Tenax Therapeutics, Inc., with holdings reaching up to 10.3% of the common stock.
Summary
- Dellora Investments Master Fund LP reported beneficial ownership of 305,257 shares of Tenax Therapeutics, Inc. common stock, representing 9.0% of the class.
- Dellora Investments LP and Kevin Pyun each reported beneficial ownership of 351,071 shares of Tenax Therapeutics, Inc. common stock, representing 10.3% of the class.
- The ownership percentages are based on 3,408,906 shares of common stock outstanding as of October 31, 2024, as reported by Tenax Therapeutics in its Form 10-Q filed on November 13, 2024.
- Dellora Investments LP serves as an investment adviser to private funds, including Dellora Investments Master Fund, LP, and Kevin Pyun is a Principal of Dellora Investments LP.
- The reporting persons explicitly stated that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Tenax Therapeutics, Inc.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive. While a 13G is a routine disclosure, the acquisition of a significant stake by an institutional investor can be perceived as a vote of confidence in the company, potentially attracting further investor interest. There are no negative implications within the filing itself.
Positives
- The disclosure of a significant ownership stake by an investment fund like Dellora Investments may signal institutional confidence in Tenax Therapeutics.
- Increased institutional ownership can sometimes lead to greater market visibility and liquidity for the stock.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding Tenax Therapeutics' future operations or financial performance.
Industry Context
This filing indicates a significant passive investment by an institutional fund in a publicly traded company, a common occurrence in the financial markets where investment firms acquire stakes for portfolio diversification and potential capital appreciation.
Stakeholder Impact
- Shareholders: May view the increased institutional ownership as a positive signal, potentially leading to increased investor confidence and interest in the stock.
- Company Management: Awareness of a significant passive shareholder may influence strategic decisions, though the filing explicitly states no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 2024-10-31 | Date as of which 3,408,906 shares of common stock were outstanding, used for ownership percentage calculation. |
| 2024-11-13 | Date Tenax Therapeutics, Inc. filed its Form 10-Q with the SEC, reporting shares outstanding. |
| 2025-01-08 | Date of event which required the filing of this Schedule 13G amendment. |
| 2025-01-15 | Date the Schedule 13G Amendment No. 1 was signed by Kevin Pyun on behalf of the reporting persons. |
Keywords
Tenax Therapeutics, Dellora Investments, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.